Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol

A. Branchi, A. M. Fiorenza, A. Torri, F. Muzio, C. Berra, E. Colombo, E. Dalla Valle, A. Rovellini, D. Sommariva

Research output: Contribution to journalArticle

Abstract

Background and Aim: It has been reported that atorvastatin increases high-density lipoprotein cholesterol (HDL-C) more in patients with low than in those with high baseline HDL-C levels. This may have a biological explanation, but also suggests a statistical artifact known as the regression to the mean. Methods and Results: Atorvastatin 10 mg/day led to a 4% increase in HDL-C after two months in 67/121 patients with hypercholesterolemia (55%), who had lower baseline HDL-C levels than the patients in whom HDL-C did not increase. In the patients with baseline HDL-C below the median, HDL-C significantly increased whereas no change was observed in patients with baseline HDL-C above the median. The correlation coefficient between pre- and post-treatment HDL-C was 0.84, thus suggesting a regression to the mean. However, the regression artifact did not entirely explain the increase in HDL-C in patients with low baseline HDL-C or the lack of an increase in those with high baseline HDL-C. The adjusted mean increase was 5.4% in patients with low pretreatment HDL-C, and 2.4% in the patients with high pretreatment HDL-C. Multiple regression analysis with the changes in HDL-C as the dependent variable showed that baseline HDL-C and the changes in serum triglycerides independently contributed to the change in HDL-C levels. Conclusions: Atorvastatin 10 mg/day increases HDL-C more in patients with low pretreatment HDL-C levels, an effect that seems to be related to the hypotriglyceridemic activity of the drug.

Original languageEnglish
Pages (from-to)24-28
Number of pages5
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume12
Issue number1
Publication statusPublished - Feb 2002

Fingerprint

high density lipoprotein cholesterol
HDL Cholesterol
pretreatment
Atorvastatin Calcium
Artifacts
hypercholesterolemia
Hypercholesterolemia

Keywords

  • Atorvastatin
  • HDL cholesterol
  • Regression to the mean artifact
  • Triglycerides

ASJC Scopus subject areas

  • Food Science
  • Medicine (miscellaneous)
  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol. / Branchi, A.; Fiorenza, A. M.; Torri, A.; Muzio, F.; Berra, C.; Colombo, E.; Dalla Valle, E.; Rovellini, A.; Sommariva, D.

In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 12, No. 1, 02.2002, p. 24-28.

Research output: Contribution to journalArticle

Branchi, A. ; Fiorenza, A. M. ; Torri, A. ; Muzio, F. ; Berra, C. ; Colombo, E. ; Dalla Valle, E. ; Rovellini, A. ; Sommariva, D. / Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol. In: Nutrition, Metabolism and Cardiovascular Diseases. 2002 ; Vol. 12, No. 1. pp. 24-28.
@article{2b8d201f04af413f9ea2a586e30d6f53,
title = "Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol",
abstract = "Background and Aim: It has been reported that atorvastatin increases high-density lipoprotein cholesterol (HDL-C) more in patients with low than in those with high baseline HDL-C levels. This may have a biological explanation, but also suggests a statistical artifact known as the regression to the mean. Methods and Results: Atorvastatin 10 mg/day led to a 4{\%} increase in HDL-C after two months in 67/121 patients with hypercholesterolemia (55{\%}), who had lower baseline HDL-C levels than the patients in whom HDL-C did not increase. In the patients with baseline HDL-C below the median, HDL-C significantly increased whereas no change was observed in patients with baseline HDL-C above the median. The correlation coefficient between pre- and post-treatment HDL-C was 0.84, thus suggesting a regression to the mean. However, the regression artifact did not entirely explain the increase in HDL-C in patients with low baseline HDL-C or the lack of an increase in those with high baseline HDL-C. The adjusted mean increase was 5.4{\%} in patients with low pretreatment HDL-C, and 2.4{\%} in the patients with high pretreatment HDL-C. Multiple regression analysis with the changes in HDL-C as the dependent variable showed that baseline HDL-C and the changes in serum triglycerides independently contributed to the change in HDL-C levels. Conclusions: Atorvastatin 10 mg/day increases HDL-C more in patients with low pretreatment HDL-C levels, an effect that seems to be related to the hypotriglyceridemic activity of the drug.",
keywords = "Atorvastatin, HDL cholesterol, Regression to the mean artifact, Triglycerides",
author = "A. Branchi and Fiorenza, {A. M.} and A. Torri and F. Muzio and C. Berra and E. Colombo and {Dalla Valle}, E. and A. Rovellini and D. Sommariva",
year = "2002",
month = "2",
language = "English",
volume = "12",
pages = "24--28",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier B.V.",
number = "1",

}

TY - JOUR

T1 - Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol

AU - Branchi, A.

AU - Fiorenza, A. M.

AU - Torri, A.

AU - Muzio, F.

AU - Berra, C.

AU - Colombo, E.

AU - Dalla Valle, E.

AU - Rovellini, A.

AU - Sommariva, D.

PY - 2002/2

Y1 - 2002/2

N2 - Background and Aim: It has been reported that atorvastatin increases high-density lipoprotein cholesterol (HDL-C) more in patients with low than in those with high baseline HDL-C levels. This may have a biological explanation, but also suggests a statistical artifact known as the regression to the mean. Methods and Results: Atorvastatin 10 mg/day led to a 4% increase in HDL-C after two months in 67/121 patients with hypercholesterolemia (55%), who had lower baseline HDL-C levels than the patients in whom HDL-C did not increase. In the patients with baseline HDL-C below the median, HDL-C significantly increased whereas no change was observed in patients with baseline HDL-C above the median. The correlation coefficient between pre- and post-treatment HDL-C was 0.84, thus suggesting a regression to the mean. However, the regression artifact did not entirely explain the increase in HDL-C in patients with low baseline HDL-C or the lack of an increase in those with high baseline HDL-C. The adjusted mean increase was 5.4% in patients with low pretreatment HDL-C, and 2.4% in the patients with high pretreatment HDL-C. Multiple regression analysis with the changes in HDL-C as the dependent variable showed that baseline HDL-C and the changes in serum triglycerides independently contributed to the change in HDL-C levels. Conclusions: Atorvastatin 10 mg/day increases HDL-C more in patients with low pretreatment HDL-C levels, an effect that seems to be related to the hypotriglyceridemic activity of the drug.

AB - Background and Aim: It has been reported that atorvastatin increases high-density lipoprotein cholesterol (HDL-C) more in patients with low than in those with high baseline HDL-C levels. This may have a biological explanation, but also suggests a statistical artifact known as the regression to the mean. Methods and Results: Atorvastatin 10 mg/day led to a 4% increase in HDL-C after two months in 67/121 patients with hypercholesterolemia (55%), who had lower baseline HDL-C levels than the patients in whom HDL-C did not increase. In the patients with baseline HDL-C below the median, HDL-C significantly increased whereas no change was observed in patients with baseline HDL-C above the median. The correlation coefficient between pre- and post-treatment HDL-C was 0.84, thus suggesting a regression to the mean. However, the regression artifact did not entirely explain the increase in HDL-C in patients with low baseline HDL-C or the lack of an increase in those with high baseline HDL-C. The adjusted mean increase was 5.4% in patients with low pretreatment HDL-C, and 2.4% in the patients with high pretreatment HDL-C. Multiple regression analysis with the changes in HDL-C as the dependent variable showed that baseline HDL-C and the changes in serum triglycerides independently contributed to the change in HDL-C levels. Conclusions: Atorvastatin 10 mg/day increases HDL-C more in patients with low pretreatment HDL-C levels, an effect that seems to be related to the hypotriglyceridemic activity of the drug.

KW - Atorvastatin

KW - HDL cholesterol

KW - Regression to the mean artifact

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=0036463826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036463826&partnerID=8YFLogxK

M3 - Article

C2 - 12125226

AN - SCOPUS:0036463826

VL - 12

SP - 24

EP - 28

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 1

ER -